HIGHLANDS RANCH Colorado, April 14, 2021 Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced the appointment of Mimi Guarneri, MD, FACC as an independent consultant serving in the role of Medical…

Vivos management to present at 9:00 am EDT on April 14, 2021 HIGHLANDS RANCH Colorado, April 12, 2021 Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced that Kirk Huntsman, Chief…

Vivos to offer MyoCorrect via telemedicine for all Vivos-trained clinicians to use as therapeutic protocol in tandem with the Vivos System HIGHLANDS RANCH   Colorado, March 22, 2021 Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive…

Full Year Revenue Increase of 15% Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH   Colorado, March 22, 2021 Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today reported…

Vivos management to present at 11:40 am Eastern Time on March 25, 2021 Colorado, September 23, 2021 HIGHLANDS RANCH, Colo., January 29, 2021 – Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today…

Internationally Recognized Medical and Dental Industry Veterans Will Work Closely with Vivos Management to Drive Further Commercial Success HIGHLANDS RANCH Colorado, January 29, 2021 HIGHLANDS RANCH, Colo., January 29, 2021 – Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including…

Call Scheduled for Thursday, March 25, 2021 at 5:00 pm ET HIGHLANDS RANCH   Colorado, March 18, 2021 HIGHLANDS RANCH, Colo., March 18, 2021 – Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today…

Vivos management to present at 1:30 pm Eastern Time on March 23, 2021 HIGHLANDS RANCH   Colorado, March 1, 2021 HIGHLANDS RANCH, Colo., March 11, 2021 – Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep…

Vivos management to present at 11:30 am Eastern Time on March 16, 2021 HIGHLANDS RANCH   Colorado, March 1, 2021 Vivos Therapeutics, Inc. (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (OSA), today announced that Kirk Huntsman,…

Physicians and Dentists Collaborate to Offer Vivos System Treatment to Patients Suffering from Sleep Apnea HIGHLANDS RANCH   Colorado, March 8, 2021 Vivos Therapeutics, Inc. (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced the opening of…